

Motavizumab

Cat. No.:	HY-P99209
CAS No.:	677010-34-3
Target:	RSV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research ^[1] .								
In Vitro	Motavizumab shows activity after F protein initiates interaction with the cell membrane and before virus transcription ^[2] . Motavizumab inhibits F protein-mediated cell-to-cell fusion ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	<p>Motavizumab (intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once) treatment shows reductions on RSV replication and concentrations of cytokine and chemokines in RSV-infected mice^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Seven-week-old female, pathogen-free BALB/c mice intranasally inoculated with 106.5 PFU RSV-A2^[1]</td> </tr> <tr> <td>Dosage:</td> <td>1.25 mg in 0.1 ml of PBS/per mouse</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once</td> </tr> <tr> <td>Result:</td> <td>Resulted in significant reductions of RSV loads compared with untreated controls on days 1 and 5. Showed lower BAL concentrations of IL-1α, IL-12p70, TNF-α and IFN-γ and serum IL-10 and KC compared with RSV-infected untreated mice.</td> </tr> </table>	Animal Model:	Seven-week-old female, pathogen-free BALB/c mice intranasally inoculated with 106.5 PFU RSV-A2 ^[1]	Dosage:	1.25 mg in 0.1 ml of PBS/per mouse	Administration:	Intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once	Result:	Resulted in significant reductions of RSV loads compared with untreated controls on days 1 and 5. Showed lower BAL concentrations of IL-1 α , IL-12p70, TNF- α and IFN- γ and serum IL-10 and KC compared with RSV-infected untreated mice.
Animal Model:	Seven-week-old female, pathogen-free BALB/c mice intranasally inoculated with 106.5 PFU RSV-A2 ^[1]								
Dosage:	1.25 mg in 0.1 ml of PBS/per mouse								
Administration:	Intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once								
Result:	Resulted in significant reductions of RSV loads compared with untreated controls on days 1 and 5. Showed lower BAL concentrations of IL-1 α , IL-12p70, TNF- α and IFN- γ and serum IL-10 and KC compared with RSV-infected untreated mice.								

REFERENCES

[1]. Mejías A, et al. Motavizumab, a neutralizing anti-Respiratory Syncytial Virus (Rsv) monoclonal antibody significantly modifies the local and systemic cytokine responses induced by Rsv in the mouse model. *Virol J.* 2007 Oct 25;4:109.

[2]. Huang K, et al. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. *J Virol.* 2010 Aug;84(16):8132-40.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA